Table 2A.

Meta regression analysis for Disease free survival.

Delta DFS						DFS hazard ratio
Variable	Beta coefficient	Studies (N)	p value	SE	95 % CI	Beta coefficient	N studies	p value	SE	95 % CI
Final year of accrual	0.41	9	0.27	84.98	−200.54 to 201.36	−0.12	9	0.75	5.64	−13.46 to 13.22
Duration of bisphosphonates	0.19	9	0.63	91.74	−216.74 to 217.12	−0.25	9	0.51	5.50	−13.26 to 12.76
Median age	−0.085	7	0.86	107.5	−276.42 to 276.25	0.41	7	0.36	5.87	−14.68 to 15.50
Post-menopausal	−0.29	9	0.45	89.46	−211.83 to 211.25	0.48	7	0.19	4.98	−12.32 to 13.28
pNode+	−0.62	9	0.07	59.67	−144.72 to 140.48	0.42	9	0.25	4.63	−10.53 to 11.37
>=pT3	−0.68	5	0.14	75.72	−241.65 to 240.29	0.46	6	0.36	4.71	−12.62 to 13.54
HR negative	−0.72	7	0.06	56.65	−146.34 to 144.90	0.82	7	0.023	2.97	−6.81 to 8.45
Grade 2	0.21	6	0.68	94.33	−261.69 to 262.11	−0.11	5	0.84	5.16	−16.53 to 16.31
Grade 3	−0.71	7	0.07	67.98	−175.46 to 174.04	0.48	7	0.27	4.99	−12.35 to 13.31
Received NACT/ACT	−0.76	9	0.02	60.24	−143.20 to 141.68	0.66	9	0.054	4.28	−9.46 to 10.78
Taxane%	−0.47	6	0.34	50.84	−141.62 to 140.68	0.48	6	0.34	0.91	−2.05 to 3.01
Anthracycline%	−0.88	6	0.02	26.99	−75.82 to 74.06	0.39	6	0.45	0.95	−2.25 to 3.03

SE−standard error, CI- confidence interval, HR = hormone receptor, NACT = neoadjuvant chemotherapy. ACT = Adjuvant chemotherapy, DFS = disease free survival.